AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 18 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (CRXL) announced that it has expanded the Research Plan of its Cooperative Research and Development Agreement with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID).
The NIAID is part of the United States of America's primary biomedical research institute, the National Institutes of Health (NIH). In May 2002, Crucell entered into an agreement with the NIAID to develop an Ebola vaccine. The Research Plan of this agreement has now been expanded to include the development of vaccines to protect against Marburg and Lassa infections.
The vaccines against these diseases will be based on Crucell's vaccination platform, AdVac, and produced on Crucell's human cell line, PER.C6. The NIAID will create modified Ebola, Marburg, and Lassa genes, which will be used in making the vaccines.
Under the terms of the agreement, Crucell has the option for exclusive commercialization rights to the Ebola, Marburg, and Lassa vaccines. The vaccines are targeted towards people living in disease endemic areas in Africa, travelers, government officials, and military personnel. The ...
Source: HighBeam Research, Ebola vaccine agreement expanded to include Marburg, Lassa...